The Utilization of Bioluminescence for the Diagnosis of Alzheimer's Disease and Related Tauopathies
Overview
In 2013, over 400,000 Americans died from Alzheimer’s disease. Early diagnosis may play a key role in increasing the success of potential preventive treatments, thus we sought to develop a new diagnostic tool for Alzheimer’s. Tau, a microtubule binding protein that contributes to Alzheimer’s disease pathology by aggregating and forming neurofibrillary tangles, is recognized as a potential biomarker for the disease, as levels of tau increase in Alzheimer’s patients. We hypothesized that, by fusing fragments of a luminescent protein to tau, we could take advantage of the process of Protein Fragment Complementation (a biological method to detect protein-protein interaction) to detect early steps in tau aggregation, which might prove to be a sensitive diagnostic tool to detect changes in tau levels and tau aggregation. In our cell-based Protein Fragment Complementation assay using tau, a luciferase molecule is divided into two halves, each half of which is attached to tau. Upon interaction of two (or more) tau molecules the two halves of luciferase are brought close together, leading to reconstitution of the luciferase enzyme which is detected by emission of a light signal. We further demonstrate that, upon addition of extracellular tau fibrils, which are present in Alzheimer’s patients, this light signal increases considerably. These data serve as proof-of-principle that call for further experimentation, including eventual plans to test our cell-based assay using cerebrospinal fluid and blood samples from Alzheimer’s versus control patients. Our results are an encouraging first step toward the development of a more efficacious diagnostic tool for Alzheimer’s disease, and possibly other diseases in which tau accumulates.
Competition history
- ISEF 2014
Resources
Related projects
ISEF · 2025
A Colorimetric Lateral Flow Assay to Detect Neurodegeneration From Tears, Phase I
ISEF · 2024
A Novel Application of a Lateral Flow Immunoassay To Develop a Non-Invasive and Rapid Whole Blood Diagnostic Method for Alzheimer's Disease
ISEF · 2019
Lighting Up the Brain: Development of a Novel Molecular Probe for the Early, Minimally-invasive Diagnosis and Treatment of Alzheimer’s Disease
ISEF · 2026
A Colorimetric Lateral Flow Assay to Detect Neurodegeneration From Tears, Phase II
ISEF · 2024
Fabrication of a Europium-Based Magnetic Nanosensor for the Detection of D-Serine in Early-Onset Alzheimer’s
ISEF · 2019
Modeling Neurodegeneration in vitro: A Dynamic Study of Tau in a Microfluidic Chamber System via Quantum Dot Labeling
ISEF · 2023
Translational Approach To Develop N-Acetylneuraminic Acid (Neu5Ac) as Biomarker for the Diagnosis of Alzheimer's Disease (AD), Year Two Project
ISEF · 2026
Point of Care Testing Device for Screening Alzheimer's Disease Using Salivary Lactoferrin as a Biomarker
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair